Quarterly Result25 Jul 2025, 07:51 pm
RPG Life Sciences Q1 FY26: Revenue up by 2.1% Y-o-Y, EBITDA margin at 24.1%
AI Summary
RPG Life Sciences Limited has announced its financial results for the first quarter ended June 30, 2025. The company's revenue from operations increased by 2.1% Y-o-Y to Rs. 168.9 crores, with a healthy EBITDA margin of 24.1%. Profit before tax remained largely in line with the previous year. The Domestic Formulations business continued to deliver market-beating growth, and the company is on track to accelerate its International Formulations and API segments. RPG Life Sciences is actively exploring inorganic growth opportunities across both formulations and APIs.
Key Highlights
- Revenue from operations increased by 2.1% Y-o-Y to Rs. 168.9 crores
- Healthy EBITDA margin of 24.1%
- Profit before tax remained largely in line with the previous year
- Domestic Formulations business delivering market-beating growth
- Actively exploring inorganic growth opportunities across both formulations and APIs